Programme & Abstracts

(click on title to view abstract of presentation)

Date: 26th November 2008
09.00 - 09.20	Registration
09.20 - 09.30	Welcome and introduction Ottilia Saxl, CEO, Institute of Nanotechnology
Plenary Session: Frontiers in Nanomedicine Chair: Ottilia Saxl , CEO, Institute of Nanotechnology, UK
09.30 - 10.10	‘Nanobiotechnology for Development of Therapeutics and Diagnostics: Science and Business Perspectives’ Dr. Mostafa Analoui, Senior Director, Pfizer Global Research and Development
10.15 - 10.45	‘Is Regenerative Medicine Ready for Translation onto Clinical Products?’ Prof. Dame Julia Polak, Director, Tissue Engineering and Regenerative Medicine Centre, Imperial College London What is Regenerative Medicine Current scientific challenges, both short and long term. Regulatory issues What we have learnt from the initial clinical applications and what we would like to happen in future
10.50 - 11.20	Refreshments
Session 2: Commercialising Nanotechnology – Opportunities and Challenges Chair: David Tolfree, Vice President of MANCEF, UK
11.20 - 11.45	‘Successful Commercialization – The Ultimate Goal’ Dr. Robert Mehalso, CEO, Microtec Associates, USA
11.50 - 12.15	‘Six Disruptive Products in Medical and Biomedical Markets based on MNT’ Dr. Malcolm Wilkinson, Director, Technology For Industry Ltd, UK
12.20 - 13.30	Lunch
Session 3: Advances in Tissue Engineering and Regenerative Medicine
13.30 - 13.55	‘Formation of Bone Form Injectable Biomaterials’ Prof. Jöns Hilborn, Prof. of Polymer Chemistry, Uppsala University, President-Tissue Engineering International and Regenerative Medicine Society Injection gives minimal invasive procedures The injected material attracts body own stem cells New vascularised bone is formed upon material degradation
14.00 - 14.25	‘Rapid Engineering of Nano-Fibrous Collagen Tissues: While-u-wait Bedside Grafts?’ Prof. Robert Brown, UCL Tissue Repair & Engineering Centre, UK
14.30 - 14.55	‘Patient Benefits from Nanomaterials’ David Farrar, Technology Manager – Biomaterials, Smith & Nephew Technologies include nanocrystalline silver, nanocomposites, nanotextured surfaces and nanofibre scaffolds Applications for these technologies are within infection control, wound healing, fracture and soft tissue fixation, orthopaedic implant fixation
15.00 - 15.30	Refreshments
Workshop: Commercialising Nanotechnology – Evolution or Revolution? Chair: David Tolfree, Vice President of MANCEF, UK
15.30 - 15.55	‘ How to Make a Successful Diagnostic Product from MNT ’ Dr Andrew Campitelli, MiniFAB (AUST) Pty Ltd, Australia Product development strategies for MNT diagnostic systems. A practical guide to the “idea - concept - labbench - prototype - product” development journey. Examples of POC platforms in healthcare (including SmartHEALTH for cancer diagnostics).
16.00 - 16.25	‘Medimate, Commercialization of a Microfluidic Device to Monitor Lithium in Blood, as a Self Test at Home or at the Doctor’s Office’ Steven Staal, Medimate BV, The Netherlands
16.30 - 16.55	‘Microfluidics for Medical Diagnostics, Opportunities and Barriers for Commercialization’ Henne van Heeren, Enabling MNT, The Netherlands Microfluidics will be a key element of many future medical diagnostic products. New diagnostic devices can only be successfully developed with the active involvement of all (future) stakeholders. There is no such thing yet as a standard technology for microfluidics.
17.00 - 17.30	Panel Discussion
17.30	Close of Day 1

Date: 27th November 2008
09.00 - 09.15	Welcome: Professor Shervanthi Homer-Vanniasinkam, Consultant Vascular Surgeon, Leeds General Infirmary Professor of Translational Vascular Medicine, Leeds Medical School
Plenary Session: Medical Nanotechnology- Challenges and Opportunities Chair: Professor Shervanthi Homer-Vanniasinkam, Consultant Vascular Surgeon, Leeds General Infirmary Professor of Translational Vascular Medicine, Leeds Medical School
09.20 - 09.45	Vladimir Kozharnovich, UNIDO
09.50 - 10.15	‘ Nanomedicine: Changing the Future of Healthcare’ ’ Dr. Franklin Schuling, Sector Head/Focal Area Owner, Molecular & Nuclear Medicine Philips Research Europe, The Netherlands
10.20 - 10.35	‘ Title t.b.c. ’ Javier Bonal, European Commission, Belgium
10.40 - 11.10	Refreshments
Session 4: Novel Devices, Nanosensors and Diagnostics Chair:
11.10 - 11.35	‘ Lab-on-a-Chip as a Tool In the Biomedical Sciences ’ Prof. Jonathan M. Cooper, FREng, FRSE "Professor of Bioelectronics and Bioengineering, Department of Electronics, University of Glasgow, UK Use of Lab-on-a-Chip for Cell Based Assays Comparison of Hgh Throughput Microtitre Formats with Microfluidic Methods New and Innovative Methods for Screening Drugs New Diagnostic Sensors
11.40 - 12.05	‘Sensors Based on Miniature Bridges, Diving Boards and Lids’ Prof. Anja Boisen, Section Leader of NanoSystems Engineering (NSE), Project Leader: Nanoprobes, Technical University of Denmark, DTU Nanotech - Department of Micro- and Nanotechnology Micro and Nano Mechanical sensors with integrated read-out. The integrated read-out allows for highly compact, portable and distributed sensors Autonomous polymer systems where coloured marker molecules are loaded in a small volume closed by a flexible lid. The lid is coated with specific detector molecules which bind the molecules under investigation. The binding of molecules causes the lid to deflect and the marker molecules are released and can be detected by the naked eye
12.10 - 12.35	‘ Title t.b.c. ’ Prof. Bertrand Tavitian, EMIL project coordinator, CEA
12.40 - 14.00	Lunch
Session 5: Cancer, Congenital and Degenerative disease Chair:
14.00 - 14.25	‘Foresighting 21st Century Medicine: Anticipating on Technology Options and their Embedment in Healthcare Practices’ Douglas Robinson, University of Twente, Netherlands
14.30 - 14.55	Andreas Jordan, Magforce Nanotechnologies
15.00 - 15.25	Stephen Willard, CEO, Flammel Technologies
15.30 - 15.55	‘The Future of Intelligent Neuroprosthetic Implants’ Prof. Rolf Eckmiller (Emeritus), Professor and Head, Div. Neural Computation, Dept. Computer Science, University of Bonn, Germany Factors driving the development, production and application of new generation implantable, learning neuroprosthetic devices Intelligent technology-based therapies for degenerative diseases The concept of interactive neuroimplants and bi-directional interaction of the human nervous system Application and time frame for the Intelligent, implantable neuroprosthetic devices to the market
16.00	Conference close

For further information contact Carrie Smith, carrie.smith@nano.org.uk

21st Century Medicine: Breakthroughs and Challenges

Programme & Abstracts

21st Century Medicine:
Breakthroughs and Challenges